AbbVie Opts to Acquire Mitokinin

AbbVie has purchased an exclusive right to acquire Mitokinin, a biotech company developing PINK1-targeted therapeutics for neurodegenerative diseases, following completion of IND enabling studies on Mitokinin's lead PINK1 compound.

Mitokinin's novel PINK1 compounds selectively increase the activity of PINK1, a master regulator of mitochondrial quality control that is genetically linked to Parkinson's disease. 
By increasing PINK1 activity, Mitokinin aims to address the mitochondrial dysfunction contributing to Parkinson's disease pathogenesis and progression.

Mitokinin will receive an upfront payment and will continue developing its PINK1 activator program through completion of IND enabling studies for its lead compound.

"We're thrilled to be working with the world-class neuroscience team at AbbVie to bring our PINK1 program forward," said Daniel de Roulet, Co-Founder and CEO at Mitokinin. "We look forward to executing on the collaborative research plan, and most of all, to developing much needed therapeutics for Parkinson's disease patients."